


IN THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-10 (cancelled)

11. (New) A compound of the general formula (I):



wherein:

A, B, C and D are each independently a methine group or a nitrogen atom, said methine group optionally having a substituent(s) selected from the group consisting of a halogen atom, a cyano group, a lower alkyl group, a C₃-C₉ cycloalkyl group, a halo-lower alkyl group, a hydroxy group, a lower alkoxy group, a halo-lower alkoxy group, a lower alkoxy carbonyl group, a lower alkylsulfonyl group, a lower alkylsulfonyloxy group, a group represented by -N(R²)R³, and a group represented by -Q¹-Ar¹, wherein at least one of A, B, C and D is a methine group;

Ar¹ is an aryl group or a heteroaryl group, each of which may optionally have a substituent(s) selected from the group consisting of a halogen atom, a nitro group, a hydroxy group, a lower alkyl group, a halo-lower alkyl group, a hydroxy-lower alkyl group, a C₃-C₆ cycloalkyl group, a lower alkenyl group, a lower alkoxy group, a halo-lower alkoxy group, a lower alkylthio group, a lower alkylsulfonyl group, a carboxy group, a lower alkanoyl group, a lower alkoxy carbonyl group, a lower alkanoylamino group and a group represented by -Q²-Ar²;

Ar² is an aryl group or a heteroaryl group, each of which may optionally have a substituent(s) selected from the group consisting of a halogen atom, a cyano group, a lower alkyl group, a halo-lower alkyl group, a hydroxy-lower alkyl group, a hydroxy group, a lower alkoxy group, a halo-


or a pharmaceutically acceptable salt or ester thereof.

12. (New) The compound of claim 1 wherein A and D are each independently an unsubstituted methine group or a nitrogen atom; one of B and C is a methine group having a halo-lower alkyl group or a group represented by $-Q^1-Ar^1$, and the other is an unsubstituted methine group or a nitrogen atom; or a pharmaceutically acceptable salt or ester thereof.

13. (New) The compound of claim 1 wherein A, B and D are each independently an unsubstituted methine group; and C is a methine group having a halo-lower alkyl group or a group represented by $-Q^1-Ar^1$; or a pharmaceutically acceptable salt or ester thereof.

14. (New) The compound of claim 1 wherein A is an unsubstituted methine group; one or both of B and D is a nitrogen atom; and C is a methine group having a halo-lower alkyl group or a group represented by $-Q^1-Ar^1$; or a pharmaceutically acceptable salt or ester thereof.

15. (New) The compound of claim 1 wherein E is a group represented by the following formulae (E10):



and R^4 is a hydrogen atom, a lower alkyl group, an aralkyl group or an aryl group; or a pharmaceutically acceptable salt or ester thereof.

16. (New) The compound of claim 1 wherein E is a group represented by the following formulae (E11):



and R⁴ is a hydrogen atom, a lower alkyl group, an aralkyl group or an aryl group; or a pharmaceutically acceptable salt or ester thereof.


17. (New) The compound of claim 1 wherein R¹ is a lower alkyl group; or a pharmaceutically acceptable salt or ester thereof.

18. (New) The compound of claim 1 which is selected from the group consisting of:

- (1) 2-(trans-4-tert-butylsulfonylaminocyclohexyl)-5-(trifluoromethyl)benzimidazole;
- (2) 2-(trans-4-tert-butylsulfonylaminocyclohexyl)-5-(2-methyltetrazol-5-yl)benzimidazole;
- (3) 2-(trans-4-tert-butylsulfonylaminocyclohexyl)-5-phenylbenzimidazole;
- (4) 2-(trans-4-tert-butylsulfonylaminocyclohexyl)-5-(2-fluorophenyl)imidazo[4,5-b]pyridine;
- (5) 8-(trans-4-tert-butylsulfonylaminocyclohexyl)-2-(2-fluorophenyl)purine;
- (6) 8-(cis-4-tert-butylsulfonylaminocyclohexyl)-2-(2-fluorophenyl)purine;
- (7) 8-(trans-4-tert-butylsulfonylaminocyclohexyl)-2-(4-fluorophenyl)purine;
- (8) 8-(cis-4-tert-butylsulfonylaminocyclohexyl)-2-(4-fluorophenyl)purine;
- (9) 8-(trans-4-tert-butylsulfonylaminocyclohexyl)-2-phenylpurine;
- (10) 8-(cis-4-tert-butylsulfonylaminocyclohexyl)-2-phenylpurine;
- (11) 5-(2,4-difluorophenyl)-2-(trans-4-isopropylsulfonylaminocyclohexyl)-imidazo[4,5-b]pyridine;
- (12) 5-(2,4-difluorophenyl)-2-(cis-4-isopropylsulfonylaminocyclohexyl)imidazo[4,5-b]pyridine;
- (13) 2-(trans-4-methylsulfonylaminocyclohexyl)-5-phenylbenzimidazole;
- (14) 5-phenyl-2-(trans-4-p-tolylsulfonylaminocyclohexyl)benzimidazole;
- (15) 2-(cis-4-methylsulfonylaminocyclohexyl)-5-phenylbenzimidazole;

- (16) 5-phenyl-2-(cis-4-p-tolylsulfonylaminocyclohexyl)benzimidazole;
 - (17) 2-{trans-4-(N-methyl-tert-butylsulfonylamino)cyclohexyl}-5-phenylbenzimidazole;
 - (18) 2-(4-tert-butylsulfonylaminopiperidin-1-yl)-5-phenylbenzimidazole;
 - (19) 2-(4-tert-butylsulfonylaminopiperidin-1-yl)-5-(2-methyltetrazol-5-yl)benzimidazole;
 - (20) 2-(3-isopropylsulfonyl-cis-3,7-diazabicyclo[3.3.0]oct-7-yl)-5-phenylbenzimidazole;
 - (21) 2-(4-isopropylsulfonyl-cis-4,9-diazabicyclo[5.3.0]dec-9-yl)-5-phenylbenzimidazole;
 - (22) 2-(1-isopropylsulfonylpiperazin-4-yl)-5-phenylbenzimidazole;
 - (23) 8-{1-(2-methylsulfonylaminophenyl)piperazin-4-yl}-2-phenylpurine;
 - (24) 5-phenyl-2-{4-(N-phenylmethylsulfonylamino)piperidin-1-yl}-benzimidazole;
and
 - (25) 2-{4-(1,1-dioxo-1λ⁶-isothiazolidin-2-yl)piperidin-1-yl}-5-phenylbenzimidazole;
- or a pharmaceutically acceptable salt thereof.

19. (New) A pharmaceutical composition comprising a therapeutically effective amount of a compound of the general formula (I):



wherein:

A, B, C and D are each independently a methine group or a nitrogen atom, said methine group optionally having a substituent(s) selected from the group consisting of a halogen atom, a cyano group, a lower alkyl group, a C₃-C₉ cycloalkyl group, a halo-lower alkyl group, a hydroxy group, a lower alkoxy group, a halo-lower alkoxy group, a lower alkoxycarbonyl group, a lower alkylsulfonyl group, a lower alkylsulfonyloxy group, a group represented by -N(R²)R³, and a group represented by -Q¹-Ar¹, wherein at least one of A, B, C and D is a methine group;

Ar¹ is an aryl group or a heteroaryl group, each of which may optionally have a substituent(s) selected from the group consisting of a halogen atom, a nitro group, a hydroxy group, a lower


lower alkoxy group, a lower alkylamino group, a di-lower alkylamino group, a lower alkanoyl group and an aryl group, or is a lower alkylene group linked to linkable position(s) of E;

R² and R³ are each independently a hydrogen atom or a lower alkyl group, or are taken together to form a lower alkylene group which may be intervened by an oxygen atom, a sulfur atom or an imino group; and

R⁵ is a hydrogen atom or a lower alkyl group, as an active ingredient;

or a pharmaceutically acceptable salt or ester thereof; and a pharmaceutically acceptable additive.

20. (New) A method for the treatment of bulimia, obesity or diabetes, which comprises administering to a mammal in need thereof a compound of the general formula (I):




wherein:

A, B, C and D are each independently a methine group or a nitrogen atom, said methine group optionally having a substituent(s) selected from the group consisting of a halogen atom, a cyano group, a lower alkyl group, a C₃-C₉ cycloalkyl group, a halo-lower alkyl group, a hydroxy group, a lower alkoxy group, a halo-lower alkoxy group, a lower alkoxycarbonyl group, a lower alkylsulfonyl group, a lower alkylsulfonyloxy group, a group represented by -N(R²)R³, and a group represented by -Q¹-Ar¹, wherein at least one of A, B, C and D is a methine group;

Ar¹ is an aryl group or a heteroaryl group, each of which may optionally have a substituent(s) selected from the group consisting of a halogen atom, a nitro group, a hydroxy group, a lower alkyl group, a halo-lower alkyl group, a hydroxy-lower alkyl group, a C₃-C₆ cycloalkyl group, a lower alkenyl group, a lower alkoxy group, a halo-lower alkoxy group, a lower alkylthio group, a lower alkylsulfonyl group, a carboxy group, a lower alkanoyl group, a lower alkoxycarbonyl group, a lower alkanoylamino group and a group represented by -Q²-Ar²;

Ar² is an aryl group or a heteroaryl group, each of which may optionally have a substituent(s) selected from the group consisting of a halogen atom, a cyano group, a lower alkyl group, a halo-lower alkyl group, a hydroxy-lower alkyl group, a hydroxy group, a lower alkoxy group, a halo-lower alkoxy group, a lower alkylamino group, a di-lower alkylamino group, a lower alkanoyl group and an aryl group;

E is a group represented by the following formulae (E1):



R⁴ is a hydrogen atom, a lower alkyl group, an aralkyl group or an aryl group; Q¹ and Q² are each independently a single bond, an oxygen atom, a carbonyl group or a group represented by –N(R⁵)–;

R¹ is a lower alkyl group or an aryl group, said aryl group optionally having a substituent(s) selected from the group consisting of a halogen atom, a cyano group, a lower alkyl group, a halo-lower alkyl group, a hydroxy-lower alkyl group, a hydroxy group, a lower alkoxy group, a halo-lower alkoxy group, a lower alkylamino group, a di-lower alkylamino group, a lower alkanoyl group and an aryl group, or is a lower alkylene group linked to linkable position(s) of E;

R² and R³ are each independently a hydrogen atom or a lower alkyl group, or are taken together to form a lower alkylene group which may be intervened by an oxygen atom, a sulfur atom or an imino group; and

Serial No.:	To be assigned
Case No.:	BY0036P
Page No.:	11

R⁵ is a hydrogen atom or a lower alkyl group;

or a pharmaceutically acceptable salt or ester thereof.